Metavant Sciences Inc

In the past, the regulatory approval of a drug was directly associated with commercial success. But drug pricing issues, different markets’ regulatory requirements and payers’ reimbursement stringency

The metabolic diseases company, Poxel SA , expects its novel antidiabetic, imeglimin, will be approved in Japan this year, through partner Sumitomo Dainippon Pharma Co., Ltd. , and also believes the